Drug Trial Radar · NCT06568939
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Last checked: Nov 20, 2026Latest source record: Oct 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
150
Planned (sponsor's estimate)
Start
Jan 20, 2025
Primary completion
Feb 2028
Study completion Feb 2028
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Aug 23, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. The purpose of this study is to assess how safe telisotuzumab vedotin is in adult participants with NSCLC. Change in disease activity and adverse events will be assessed. Telisotuzumab vedotin is an investigational drug being developed for the treatment of NSCLC. Participants will be randomly assigned a treatment of telisotuzumab vedotin in 1 of 3 arms at an 1:1:1 ratio. Each group receives intravenous (IV) infusion of telisotuzumab vedotin at different doses. Approximately 150 adult participants with c-Met overexpressing NSCLC will be enrolled in the study at approximately 80 to 90 sites worldwide. Participants will receive IV telisotuzumab vedotin at 1 of 3 dose regimens as part of a 3 year study duration. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Conditions
- Non-Small Cell Lung Cancer
- c-MET
Interventions
Telisotuzumab VedotinDrug
Intravenous (IV) Infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants with Treatment-Emergent Adverse Events (AE)s (Any-grade and Grade >= 2)Time frame: Up to Approximately 3 Years
- Percentage of Participants with Treatment-Emergent Interstitial Lung Disease (ILD)Time frame: Up to Approximately 3 Years
- Percentage of Participants with Treatment-Emergent Peripheral NeuropathyTime frame: Up to Approximately 3 Years
- Percentage of Participants with Treatment-Emergent Ocular Surface DisordersTime frame: Up to Approximately 3 Years
- Percentage of Participants with Treatment-Emergent AEs Leading to Study Drug DiscontinuationTime frame: Up to Approximately 3 Years
- Percentage of Participants with Grade 5 Treatment-Emergent AEsTime frame: Up to Approximately 3 Years
- Objective Response (OR) by Blinded Independent Central Review (BICR)Time frame: Up to Approximately 3 Years
Locations
83 sites in 7 countries. Site status is shown where the registry gives one.
Ironwood Cancer and Research Center /ID# 276370
Chandler, Arizona · Recruiting
University of Arkansas for Medical Sciences /ID# 272923
Little Rock, Arkansas · Recruiting
Start Los Angeles /ID# 284999
Los Angeles, California · Recruiting
Valkyrie Clinical Trials /ID# 271322
Los Angeles, California · Recruiting
FOMAT Medical Research - Clinica mi Salud by Focil Med /ID# 284816
Oxnard, California · Recruiting
Yale New Haven Hospital /ID# 271584
New Haven, Connecticut · Completed
Cancer Specialists of North Florida - Jacksonville - AC Skinner Parkway /ID# 270899
Jacksonville, Florida · Recruiting
Ocala Oncology Center /ID# 273697
Ocala, Florida · Recruiting
Memorial Hospital West /ID# 270313
Pembroke Pines, Florida · Recruiting
Comprehensive Hematology Oncology /ID# 270422
St. Petersburg, Florida · Recruiting
Florida Cancer Specialists - North /ID# 271995
St. Petersburg, Florida · Recruiting
Florida Cancer Specialists - East /ID# 271993
West Palm Beach, Florida · Recruiting
University Cancer and Blood Center /ID# 270969
Athens, Georgia · Recruiting
Northwest Georgia Oncology Centers /ID# 275374
Marietta, Georgia · Recruiting
Memorial University Medical Center /ID# 272467
Savannah, Georgia · Completed
Kaiser Permanente Moanalua Medical Center /ID# 272916
Honolulu, Hawaii · Recruiting
University of Illinois Hospital and Health Sciences System /ID# 275345
Chicago, Illinois · Recruiting
Illinois Cancer Specialists /ID# 274678
Niles, Illinois · Recruiting
OSF St. Francis Medical Center /ID# 281591
Peoria, Illinois · Recruiting
Springfield Clinic - First /ID# 272576
Springfield, Illinois · Recruiting
Nebraska Hematology-Oncology /ID# 272970
Lincoln, Nebraska · Recruiting
Nebraska Cancer Specialists - Omaha - Wright Street /ID# 271527
Omaha, Nebraska · Recruiting
Renown Regional Medical Center /ID# 273535
Reno, Nevada · Recruiting
Astera Cancer Care /ID# 272359
East Brunswick, New Jersey · Recruiting
Regional Cancer Care Associates /ID# 270783
Teaneck, New Jersey · Recruiting
Montefiore Medical Center - Einstein Campus /ID# 277169
The Bronx, New York · Recruiting
Clinical Research Alliance (SMO/Network/Consortium) /ID# 270455
Westbury, New York · Recruiting
FirstHealth of the Carolinas- Speciality Center /ID# 272924
Pinehurst, North Carolina · Recruiting
Mercy Health - Perrysburg Cancer Center /ID# 270536
Perrysburg, Ohio · Recruiting
Genesis Healthcare System /ID# 273361
Zanesville, Ohio · Recruiting
Guthrie Robert Packer Hospital /ID# 270316
Sayre, Pennsylvania · Recruiting
Cancer Care Associates Of York /ID# 270971
York, Pennsylvania · Recruiting
Medical University of South Carolina /ID# 273272
Charleston, South Carolina · Recruiting
Saint Francis Cancer Center - Greenville /ID# 276368
Greenville, South Carolina · Recruiting
SCRI Oncology Partners /ID# 270162
Nashville, Tennessee · Recruiting
Texas Oncology - Dallas - Worth Street /ID# 278947
Dallas, Texas · Recruiting
Texas Oncology - Northeast Texas /ID# 272000
Tyler, Texas · Recruiting
Community Cancer Trials Of Utah /ID# 276598
Ogden, Utah · Recruiting
Virginia Cancer Specialists - Fairfax /ID# 272004
Fairfax, Virginia · Recruiting
Medical Oncology Associates - Spokane /ID# 277172
Spokane, Washington · Recruiting
Showing 40 of 83 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.